Navigation Links
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:3/13/2008

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide an overview of the company, including its clinical development and discovery programs, at two upcoming investor conferences:

-- Cowen 28th Annual Health Care Conference

Presentation: Wednesday, March 19, 2008 at 8:45 a.m. Eastern Time (5:45

a.m. Pacific Time) at the Boston Marriott Copley Place in Boston,

Massachusetts

Presenting: Jack Lief, Arena's President and Chief Executive Officer

-- Lehman Brothers Eleventh Annual Global Healthcare Conference

Presentation: Thursday, March 20, 2008 at 10:45 a.m. Eastern Time (7:45

a.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florida

Presenting: Robert E. Hoffman, Arena's Vice President, Finance and

Chief Financial Officer

A live audio webcast of each presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of each presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... About Bioactive Material Bioactive ... are increasingly becoming popular due to their ability ... having a negative impact on the human health. ... tissue repair materials in surgical procedures. Bioactive materials ... glass-ceramics, and composites. The major end-users of bioactive ...
(Date:9/23/2014)... France (PRWEB) September 23, 2014 ... of laboratory personnel since 1968 and Burdinola, supplier of ... of a new filtered fume hood. , ... laboratory fume hood, Burdinola will now offer an innovative ... a wide range of chemicals, best-in-class detection technology, and ...
(Date:9/23/2014)... ATCC, the premier global biological materials resource and ... to the senior leadership team. Barbie Bigelow has joined ... and Dr. Maryellen de Mars also joins as the ... are new positions at ATCC. , ... described the additions as part of a revitalization strategy ...
(Date:9/23/2014)... September 23, 2014 Follow ... gaining steady popularity the world over, due to ... Growth in the marketplace is expected to come ... in developing countries. Several sub-Saharan countries in the ... have already implemented genetically engineered crop production strategies. ...
Breaking Biology Technology:Global Bioactive Material Market 2014-2018 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... chemical reaction that causes iron to rust plays a similarly ... healthy cells and is a process, scientists know, that contributes ... from Alzheimer,s, heart disease and stroke to cancer and the ... edition (Feb. 21, 2008) of the journal Nature, a team ...
... ... Accuracy, PITTSBURGH, Feb. 20 Applied Isotope Technologies,("AIT") ... edition of the Federal Register as a part of the methods,section of ... Recovery Act). This updated version of the method includes,a long list of ...
... TAMPA, Fla., Feb. 20 Sirion Therapeutics, ... that it has entered into an exclusive ... FL for the worldwide rights to develop ... anti- inflammatory agent norketotifen., (Logo: ...
Cached Biology Technology:Genetic pathway critical to disease, aging found 2Genetic pathway critical to disease, aging found 3Newly Published EPA RCRA Method 6800 Supports AIT Technology 2Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases 2
(Date:9/23/2014)... have encountered variants or isoforms in microRNAs (miRNAs) before, ... recent study, published in the journal Oncotarget ... abundances that depend on geographic subpopulations and gender and ... may not be the one typically listed in the ... are much more common than we had previously assumed. ...
(Date:9/23/2014)... When the body forms new tissues during ... communicate with each other. For years, scientists believed ... researchers at Carnegie Mellon University and the University ... mechanical communication is equally if not more ... of the Proceedings of the National Academy ...
(Date:9/23/2014)... are fighting a cyberwar against cancer finds that the ... , "Recent research has found that cancer is already ... we studied the interplay between cancer and the immune ... on cancer," said Rice University,s Eshel Ben-Jacob, co-author of ... of the Proceedings of the National Academy of ...
Breaking Biology News(10 mins):Slight alterations in microRNA sequences hold more information than previously thought 2Slight alterations in microRNA sequences hold more information than previously thought 3The mechanics of tissue growth 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3
... microscopic organ-on-a-chip devices that mimic the way real organs ... effects of therapies more accurately, will be discussed by ... week. Professor Don Ingber, Director of the ... will deliver the inaugural Bagrit Lecture, which will be ...
... Nitrogen pollution in our coastal ecosystems, the result of ... sewage, leads to decreased water transparency, the loss of ... speciessuch as the algae behind the renowned "red tides" ... pronounced in the Gulf of Mexico and the Caribbean. ...
... could a colorblind animal know how to change its ... will the animal,s predator "see," looking at its prey ... are addressed in article published today by a collaborative ... Hole, Mass., and the U.S. Military Academy in West ...
Cached Biology News:Media invitation: Pioneer of organ-on-a-chip technology to speak at Imperial College London 2Sewage-derived nitrogen increasingly polluting Caribbean ecosystems 2How can a colorblind animal change its colors to blend into the background? 2How can a colorblind animal change its colors to blend into the background? 3
... a partial recombinant IFNA2. Immunogen: ... is produced in E. coli. The biological ... OMIM: 147562, ... MM951100564 MA Code: ABV0P9DPB ...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Biology Products: